OncoMatch/Clinical Trials/NCT05430698
PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
Is NCT05430698 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies PD-1antibody plus GEMOX for perihilar cholangiocarcinoma.
Treatment: PD-1antibody plus GEMOX — This is an open-label,single center,non-randomized,single arm exploratory study. The objective of this study is to evaluate the efficacy and safety of PD-1 antibody plus GEMOX as postoperative adjuvant therapy in perihilar cholangiocarcinoma with positively metastatic lymph nodes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cholangiocarcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: gemcitabine-based chemotherapy
Have used gemcitabine-based chemotherapy within 6 months
Cannot have received: anti-PD-1 therapy
have used PD-1 monoclonal antibody ... within 6 months
Cannot have received: anti-PD-L1 therapy
have used ... PD-L1 monoclonal antibody treatment within 6 months
Lab requirements
Blood counts
Neutrophils ≥ 1.5*10^9/L; platelets ≥ 100*10^9/L; hemoglobin ≥ 9g/dl; serum albumin ≥ 3g/dl
Kidney function
Serum creatinine ≤ 1.5 times the upper limit of normal, and creatinine clearance ≥ 60ml/min (Cockcroft-Gault formula)
Liver function
Bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST ≤ 3 times the upper limit of normal; Child-Pugh score A period
The functional indicators of important organs meet the following requirements ... Child-Pugh score A period
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05430698 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gemcitabine-based chemotherapy, anti-PD-1 therapy, anti-PD-L1 therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages